Led Neomorph Series B ($100M) for molecular glue degrader therapeutics, with Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital participating.
Neomorph is a biotechnology company pioneering the discovery and development of molecular glue degraders to unlock new therapeutic possibilities across serious diseases
Neomorph is a biotechnology company pioneering the discovery and development of molecular glue degraders to unlock new therapeutic possibilities across serious diseases. By engineering neomorphic protein surfaces, Neomorph enables precisely targeted protein degradation of disease drivers that have historically been considered undruggable.